Big news on Covaxin:Indigenous corona vaccine steps towards approval from WHO; International health body approved the expression of interest
Hopes of getting approval from the World Health Organization (WHO) for Corona’s indigenous vaccine, Covaxin, have increased. Vaccine maker Bharat Biotech’s Expression of Interest (EOI) has been accepted by WHO. The company submitted the EOI on April 19 to get approval for Covaxin. The pre-submission meeting in the matter will now be held on June 23.
What is the significance of WHO’s emergency use approval?
- The WHO’s Emergency Use Listing examines the safety and effectiveness of a health product in a public health emergency such as a pandemic. The WHO gave emergency use approval to Pfizer’s vaccine on 31 December 2020, Oxford-AstraZeneca’s vaccine on 15 February 2021 and Johnson & Johnson’s vaccine on 12 March.
- According to the WHO, in view of the emergency situation, it is necessary to develop and approve medicines, vaccines and diagnostic tools as soon as possible. That too while meeting the standards of safety, efficiency and quality. This assessment ensures the usefulness of these products to a wider range of people during the pandemic.
Debate begins amid discussion of vaccine passport
- Recently, British Prime Minister Boris Johnson indicated that an attempt could be made to reach a consensus on a vaccine passport during the G-7 conference. His proposal is to make international travel easier, but it still has many problems. There are also many countries where due to manufacturing or other problems, vaccination has not reached full speed.
- Covaxin is being talked about in this because it has not been approved by WHO then. Foreign universities and many countries have made such rules that people who have got the WHO approved vaccine will be allowed to travel abroad without restrictions. The most affected by this will be the children studying in foreign universities, who have got Covaxin installed in India
Expected to get approval between July and September, Covaxin may get emergency use approval from WHO between July and September. The company said that regulatory approvals for Covaxin are underway in 60 countries. These include America and Brazil most affected by Corona. Application has also been given at WHO-Geneva for approval.
According to the company, Covaxin has been approved in 13 countries so far. Most of the countries are emphasizing on the vaccination of the people coming here. Those who have not been vaccinated can travel with a negative RT-PCR test report.